Meningococcal meningitis
MONDO:0018059An acute bacterial disease caused by Neisseria meningitides that presents usually, but not always, with a rash (non blanching petechial or purpuric rash), progressively developing signs of meningitis (fever, vomiting, headache, photophobia, and neck stiffness) and later leading to confusion, delirium and drowsiness. Neck stiffness and photophobia are often absent in infants and young children who may manifest nonspecific signs such as irritability, inconsolable crying, poor feeding, and a bulging fontanel. Meningococcal meningitis may also present as part of early or late onset sepsis in neonates. The disease is potentially fatal. Surviving patients may develop neurological sequelae that include sensorineural hearing loss, seizures, spasticity, attention deficits and intellectual disability.
24 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New meningitis vaccine trial aims to shield babies from deadly infection
⭐️ VACCINE ⭐️ Recruiting nowThis Phase 3 trial tests a new vaccine designed to protect infants aged 3 to 5 months against four strains of meningococcal bacteria that cause meningitis and sepsis. About 880 healthy babies will receive either the experimental vaccine or a licensed comparator vaccine. Researche…
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
-
New meningitis vaccine trial aims to protect babies
⭐️ VACCINE ⭐️ Recruiting nowThis Phase 3 trial tests a new vaccine against four types of meningococcal bacteria (A, C, Y, W135) that cause meningitis. About 1,040 healthy infants aged 6 to 11 months will receive either the experimental vaccine or a licensed comparator. Researchers will measure immune respon…
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
-
New meningitis vaccine for toddlers shows promise in major trial
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a new vaccine to protect young children (12-23 months old) against four types of meningococcal bacteria that can cause meningitis. About 1,040 toddlers will receive either the new vaccine or an existing one to see if the new vaccine is as safe and effective. The …
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
-
One shot to rule them all? new combo vaccine trial for kids begins
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial is testing a new vaccine that combines protection against several serious childhood diseases: diphtheria, tetanus, whooping cough, meningitis, and Hib. The study involves 260 children aged 2 months to 6 years to check the vaccine's safety and immune respons…
Phase: PHASE1 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:07 UTC
-
Massive meningitis study aims to improve care in brazil
Knowledge-focused Recruiting nowThis study is tracking how adults with meningitis are treated in about 30 hospitals across Brazil. Researchers will follow 624 patients during their hospital stay and after discharge to see what treatments work best and how patients recover. The goal is to gather real-world evide…
Sponsor: Hospital Israelita Albert Einstein • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New registry aims to improve meningitis treatment for kids
Knowledge-focused Recruiting nowThis study is creating a registry of 600 children under 18 with meningitis treated at hospitals across Brazil. Researchers will collect data during and after hospitalization to see how well current treatments work and what long-term problems, like hearing loss, occur. The goal is…
Sponsor: Hospital Israelita Albert Einstein • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Groundbreaking study investigates vaccine response differences across gender and sex
Knowledge-focused Recruiting nowThis study looks at how a person's sex and gender might change their immune system's reaction to the meningitis B vaccine. Researchers will compare immune responses in transgender and cisgender adults aged 18 to 50. The goal is to better understand why men and women often respond…
Phase: PHASE4 • Sponsor: University Ghent • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Massive meningitis study aims to save lives in uganda
Knowledge-focused Recruiting nowThis study in northern Uganda will track 1,100 people with meningitis symptoms and screen 10,000 HIV-positive patients for a fungal infection that can lead to meningitis. Researchers will use modern diagnostic tests to understand the causes and outcomes of the disease. The goal i…
Phase: NA • Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC